Literature DB >> 31227353

Co-administration of GM-CSF expressing RNA is a powerful tool to enhance potency of SAM-based vaccines.

Cristina Manara1, Michela Brazzoli1, Diego Piccioli1, Marianna Taccone1, Ugo D'Oro1, Domenico Maione1, Elisabetta Frigimelica2.   

Abstract

Self-amplifying mRNAs (SAM)-based vaccines have been shown to induce a robust immune response in various animal species against both viral and bacterial pathogens. Due to their synthetic nature and to the versatility of the manufacturing process, SAM technology may represent an attractive solution for rapidly producing novel vaccines, which is particularly critical in case of pandemic infections or diseases mediated by newly emerging pathogens. Recent published data support the hypothesis that Antigen Presenting Cells (APCs) are responsible for CD8+ T-cell priming after SAM vaccination, suggesting cross-priming as the key mechanism for antigen presentation by SAM vaccines. In our study we investigated the possibility to enhance the immune response induced in mice by a single immunization with SAM by increasing the recruitment of APCs at the site of injection. To enhance SAM immunogenicity, we selected murine granulocyte-macrophage colony-stimulating factor (GM-CSF) as a model chemoattractant for APCs, and developed a SAM-GM-CSF vector. We evaluated whether the use of SAM-GM-CSF in combination with a SAM construct encoding the Influenza A virus nucleoprotein (NP) would lead to an increase of APC recruitment and NP-specific immune response. We indeed observed that the administration of SAM-GM-CSF enhances the recruitment of APCs at the injection site. Consistently with our hypothesis, co-administration of SAM-GM-CSF with SAM-NP significantly improved the magnitude of NP-specific CD8+ T-cell response both in terms of frequency of cytotoxic antigen-specific CD8+ T-cells and their functional activity in vivo. Furthermore, co-immunization with SAM-GM-CSF and SAM-NP provided an increase in protection against a lethal challenge with influenza virus. In conclusion, we demonstrated that increased recruitment of APCs at the site of injection is associated with an enhanced effectiveness of SAM vaccination and might be a powerful tool to potentiate the efficacy of RNA vaccination.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GM-CSF; Influenza; Protective immunity; Self-amplifying mRNA; Vaccine

Year:  2019        PMID: 31227353     DOI: 10.1016/j.vaccine.2019.04.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

Review 2.  mRNA vaccines: Past, present, future.

Authors:  Mia Karam; Georges Daoud
Journal:  Asian J Pharm Sci       Date:  2022-06-30       Impact factor: 9.273

3.  Self-Replicating RNAs Drive Protective Anti-tumor T Cell Responses to Neoantigen Vaccine Targets in a Combinatorial Approach.

Authors:  Christian J Maine; Guilhem Richard; Darina S Spasova; Shigeki J Miyake-Stoner; Jessica Sparks; Leonard Moise; Ryan P Sullivan; Olivia Garijo; Melissa Choz; Jenna M Crouse; Allison Aguilar; Melanie D Olesiuk; Katie Lyons; Katrina Salvador; Melissa Blomgren; Jason L DeHart; Kurt I Kamrud; Gad Berdugo; Anne S De Groot; Nathaniel S Wang; Parinaz Aliahmad
Journal:  Mol Ther       Date:  2020-12-03       Impact factor: 11.454

Review 4.  mRNA vaccine for cancer immunotherapy.

Authors:  Lei Miao; Yu Zhang; Leaf Huang
Journal:  Mol Cancer       Date:  2021-02-25       Impact factor: 27.401

Review 5.  An Update on Self-Amplifying mRNA Vaccine Development.

Authors:  Anna K Blakney; Shell Ip; Andrew J Geall
Journal:  Vaccines (Basel)       Date:  2021-01-28

Review 6.  Literature Mining and Mechanistic Graphical Modelling to Improve mRNA Vaccine Platforms.

Authors:  Lorena Leonardelli; Giuseppe Lofano; Gianluca Selvaggio; Silvia Parolo; Stefano Giampiccolo; Danilo Tomasoni; Enrico Domenici; Corrado Priami; Haifeng Song; Duccio Medini; Luca Marchetti; Emilio Siena
Journal:  Front Immunol       Date:  2021-09-07       Impact factor: 7.561

7.  Single-Cell Analysis of Antigen-Specific CD8+ T-Cell Transcripts Reveals Profiles Specific to mRNA or Adjuvanted Protein Vaccines.

Authors:  Trine Sundebo Meldgaard; Fabiola Blengio; Denise Maffione; Chiara Sammicheli; Simona Tavarini; Sandra Nuti; Roland Kratzer; Duccio Medini; Emilio Siena; Sylvie Bertholet
Journal:  Front Immunol       Date:  2021-10-29       Impact factor: 7.561

8.  Local Sustained GM-CSF Delivery by Genetically Engineered Encapsulated Cells Enhanced Both Cellular and Humoral SARS-CoV-2 Spike-Specific Immune Response in an Experimental Murine Spike DNA Vaccination Model.

Authors:  Rémi Vernet; Emily Charrier; Erika Cosset; Sabine Fièvre; Ugo Tomasello; Julien Grogg; Nicolas Mach
Journal:  Vaccines (Basel)       Date:  2021-05-10

Review 9.  A new generation of vaccines based on alphavirus self-amplifying RNA.

Authors:  María Cristina Ballesteros-Briones; Noelia Silva-Pilipich; Guillermo Herrador-Cañete; Lucia Vanrell; Cristian Smerdou
Journal:  Curr Opin Virol       Date:  2020-09-05       Impact factor: 7.090

Review 10.  Self-amplifying RNA vaccines for infectious diseases.

Authors:  Kristie Bloom; Fiona van den Berg; Patrick Arbuthnot
Journal:  Gene Ther       Date:  2020-10-22       Impact factor: 5.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.